Our expert introduces some of the bioprocessing best practices required to de-risk the commercial manufacturing of cell and gene therapies. Watch our webinar to learn:

  • the principles of commercialization readiness, logical steps and the best practices to address them in process development
  • FMEA (failure mode and effects analysis) and how to use it for commercialization readiness
  • the best time to implement automation and minimize the commercialization risks
  • the key requirements for analytical methods used in the commercial processes

Spear: Dr Behnam Ahmadian Baghbaderani, Global Head of Process Development for Cell & Gene Technologies

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center